Vijay Pande, who previously ran Andreessen Horowitz's roughly $4 billion biotech practice, has left to launch VZVC, a much smaller AI-native venture fund. He argues biology is transitioning from a discovery-based science to an engineering discipline, while emphasizing that open, shared datasets—not proprietary ones—will be key to unlocking AI's potential in medicine.
Background
Vijay Pande was a Stanford computational biologist and former a16z partner who led one of the largest biotech investment efforts in venture capital history before departing last year.
- Source
- TechCrunch
- Published
- Aug 30, 2026 at 01:36 AM
- Score
- 6.0 / 10